Allogene Therapeutics (ALLO) Statistics

Allogene Therapeutics Inc (ALLO) is a biotechnology company focused on developing innovative allogeneic CAR T cell therapies for cancer treatment. As of the latest statistics, ALLO has a market capitalization of $X billion, with a price-to-sales ratio of X and a price-to-earnings ratio of X. These valuation metrics indicate the market's perception of the company's growth potential and overall financial performance. The fundamentals of ALLO are also strong, with a robust pipeline of CAR T cell therapies in various stages of development.

ALLO's stock performance has been impressive when compared to the sector. Over the past year, ALLO stock has generated a return of X%, outperforming the sector average of X%. This highlights the company's ability to deliver value to its shareholders. In terms of revenue per share, ALLO has reported $X in the latest financial period. This metric provides insight into the company's ability to generate revenue on a per-share basis, which is important for assessing its profitability. Furthermore, ALLO's Enterprise to EBITDA ratio stands at X, indicating its ability to generate operating income relative to its enterprise value.